Avenzo Therapeutics Company Profile

Background

Avenzo Therapeutics, Inc., established in August 2022 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to developing next-generation oncology therapies. The company's mission is to improve the lives of cancer patients by delivering therapies that enhance current standards of care. Leveraging deep expertise in oncology drug development, Avenzo focuses on advancing differentiated drug candidates to address cancers with high unmet medical needs.

Key Strategic Focus

Avenzo's strategic focus centers on the in-licensing and development of potentially best-in-class oncology assets, particularly targeting cyclin-dependent kinases (CDKs) and antibody-drug conjugates (ADCs). The company aims to rapidly advance these assets through clinical development to provide new treatment options for patients with advanced solid tumors, including hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Financials and Funding

Since its inception, Avenzo has successfully raised approximately $386 million through Series A and A-1 financing rounds. The Series A-1 round, closed in March 2024, was oversubscribed at $150 million and led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital. Proceeds are allocated to advancing the company's oncology pipeline, including the development of AVZO-021, a selective CDK2 inhibitor.

Pipeline Development

Avenzo's pipeline includes several promising candidates:

AVZO-021: A highly potent and selective CDK2 inhibitor, currently in a U.S.-based Phase 1 clinical study for advanced solid tumors, including HR+/HER2- metastatic breast cancer.

AVZO-023: A novel CDK4 selective inhibitor, with an Investigational New Drug (IND) application cleared by the FDA in May 2025. A Phase 1/2 clinical study is planned for the third quarter of 2025.

AVZO-1418/DB-1418: An EGFR/HER3 bispecific ADC, licensed from Duality Biotherapeutics, with plans to initiate a first-in-human clinical study in 2025.

Nectin4/TROP2 Bispecific ADC: Under an exclusive option agreement with VelaVigo, this potential first-in-class ADC is planned for IND submission in mid-2025.

Technological Platform and Innovation

Avenzo distinguishes itself through its strategic in-licensing of innovative technologies:

CDK Inhibitors: Development of selective inhibitors targeting CDK2 and CDK4, crucial enzymes in cell cycle regulation, to overcome resistance mechanisms in cancer therapy.

Antibody-Drug Conjugates (ADCs): Utilization of bispecific ADCs targeting co-expressed antigens like EGFR/HER3 and Nectin4/TROP2 to enhance therapeutic efficacy across various solid tumors.

Leadership Team

Avenzo's leadership comprises seasoned professionals with extensive experience in oncology drug development:

Athena Countouriotis, M.D.: Co-founder, President, CEO, and Chairperson. Formerly led Turning Point Therapeutics through its IPO and subsequent $4.1 billion acquisition by Bristol Myers Squibb.

Mohammad Hirmand, M.D.: Co-founder and Chief Medical Officer. Previously served as CMO at Turning Point Therapeutics and Peloton Therapeutics.

Paolo Tombesi: Chief Financial Officer. Former CFO at Turning Point Therapeutics and Epizyme, Inc.

Brian Sun, M.S., J.D.: Chief Legal Officer. Previously served as General Counsel at Turning Point Therapeutics.

Scott Lipman, M.B.A.: Chief Business Officer. Promoted in November 2024; formerly Senior Vice President, Corporate Development at Avenzo.

Leadership Changes

In October 2024, Avenzo appointed Garry Nicholson, former President of Pfizer Oncology, to its Board of Directors as an independent director.

Competitor Profile

Market Insights and Dynamics: The oncology therapeutics market is highly competitive, with significant investments in CDK inhibitors and ADCs. The market is characterized by rapid innovation and a focus on targeted therapies.

Competitor Analysis: Key competitors include:

Pfizer: Developed Ibrance (palbociclib), a CDK4/6 inhibitor for HR+/HER2- breast cancer.

Eli Lilly: Markets Verzenio (abemaciclib), another CDK4/6 inhibitor.

Novartis: Offers Kisqali (ribociclib), also targeting CDK4/6.

Daiichi Sankyo: Developed Enhertu, an ADC targeting HER2-expressing cancers.

Strategic Collaborations and Partnerships

Avenzo has established significant collaborations to enhance its pipeline:

Allorion Therapeutics: Licensed AVZO-021, a CDK2 inhibitor, and exercised an option for AVZO-023, a CDK4 inhibitor.

Duality Biotherapeutics: Exclusive global license for AVZO-1418/DB-1418, an EGFR/HER3 bispecific ADC.

VelaVigo: Exclusive option agreement for a Nectin4/TROP2 bispecific ADC.

Gilead Sciences: Clinical study collaboration to evaluate AVZO-021 in combination with Trodelvy (sacituzumab govitecan-hziy) for HR+/HER2- metastatic breast cancer.

Operational Insights

Avenzo's strategic in-licensing approach allows rapid advancement of clinical-stage assets, positioning the company competitively in the oncology therapeutics market. The leadership team's proven track record in oncology drug development and successful exits enhances Avenzo's credibility and operational effectiveness.

Strategic Opportunities and Future Directions

Avenzo plans to continue expanding its pipeline through strategic in-licensing of clinical-stage oncology assets, aiming to initiate multiple clinical trials by mid-2025. The company is also considering an initial public offering within the next two years to further support its growth and development objectives.